Please enable JavaScript to continue using this application.

Compare $AKBA vs $LYEL | Chartloom

Compare

$AKBA vs $LYEL

Akebia Therapeutics Inc · Lyell Immunopharma Inc

AKBA

Akebia Therapeutics Inc

LYEL

Lyell Immunopharma Inc

Compare $AKBA vs $LYEL

Comparing Akebia Therapeutics Inc and Lyell Immunopharma Inc

AKBAAkebia Therapeutics Inc

LYELLyell Immunopharma Inc

AKBAAkebia Therapeutics Inc

Market cap

$215M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1.35x

Rev growth (TTM)

7.5%

YTD performance

-48.3%

52W performance

-71.9%

FCF yield

13.7%

LYELLyell Immunopharma Inc

Market cap

$203M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

16,911.71x

Rev growth (TTM)

-55.0%

YTD performance

-69.9%

52W performance

-52.3%

FCF yield

-86.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AKBA

LYEL

Detailed metrics comparison

AKBA

Akebia Therapeutics Inc

LYEL

Lyell Immunopharma Inc

Market Cap

AKBA$215M

LYEL$203M

Enterprise Value

AKBA$252M

LYEL$130M

Price

AKBA$0.80

LYEL$8.71

P/E Ratio

AKBAN/A

LYELN/A

P/S Ratio

AKBA0.98x

LYEL7,526.09x

EV/Sales

AKBA1.15x

LYEL4,822.94x

EV/EBITDA

AKBA49.22x

LYEL0.00x

P/B Ratio

AKBA9.58x

LYEL0.97x

P/FCF Ratio

AKBA7.30x

LYELN/A

EV/FCF

AKBA8.54x

LYEL-0.74x

PEG Ratio

AKBAN/A

LYELN/A

Forward P/E (NTM)

AKBAN/A

LYELN/A

Forward P/S (NTM)

AKBA1.35x

LYEL16,911.71x

Revenue (TTM)

AKBA$219M

LYEL$27K

Revenue Growth (YoY)

AKBA7.5%

LYEL-55.0%

Forward Rev Growth

AKBA-33.0%

LYEL7184.7%

Gross Margin (TTM)

AKBA81.5%

LYEL0.0%

Operating Margin (TTM)

AKBA0.0%

LYEL0.0%

EBITDA Margin (TTM)

AKBA-1.9%

LYEL-669059.3%

Net Margin (TTM)

AKBA-13.5%

LYEL-920285.2%

FCF Margin (TTM)

AKBA13.4%

LYEL-648763.0%

Net Income (TTM)

AKBA$-30M

LYEL$-248M

FCF (TTM)

AKBA$29M

LYEL$-175M

EPS (TTM)

AKBA-$0.11

LYEL-$10.64

ROE (TTM)

AKBA-9374.0%

LYEL-9162.0%

ROA (TTM)

AKBA-817.0%

LYEL-7050.0%

ROIC (TTM)

AKBA-1321.0%

LYEL-9162.0%

Cash

AKBA$156M

LYEL$73M

Debt

AKBA$192M

LYEL$0

Net Cash/Debt

AKBA$-37M

LYEL$73M

Current Ratio (TTM)

AKBA1.43x

LYEL5.36x

Quick Ratio (TTM)

AKBA1.31x

LYEL5.12x

Debt/Equity (TTM)

AKBA7.69x

LYEL0.00x

Debt/Assets (TTM)

AKBA0.0%

LYEL0.0%

Interest Coverage (TTM)

AKBAN/A

LYELN/A

Net Debt/EBITDA (TTM)

AKBA0.00x

LYEL0.00x

Beta

AKBA0.20

LYEL-0.04

52W Performance

AKBA-71.9%

LYEL-52.3%

YTD Performance

AKBA-48.3%

LYEL-69.9%

% from 52W High

AKBA-75.0%

LYEL-80.6%

% from 52W Low

AKBA0.0%

LYEL6.1%

Asset Turnover (TTM)

AKBA0.60x

LYEL0.00x

FCF Yield (TTM)

AKBA13.7%

LYEL-86.2%

Earnings Yield (TTM)

AKBA-13.8%

LYEL-122.3%

Dividend Yield (TTM)

AKBAN/A

LYELN/A

Rule of 40

AKBA21.0

LYEL-648,818.0

EV/GP/RG

AKBAN/A

LYELN/A

Ticker research

View AKBA research View LYEL research

Metric	AKBA Akebia Therapeutics Inc	LYEL Lyell Immunopharma Inc
Market & Valuation
Market Cap	$215M	$203M
Enterprise Value	$252M	$130M
Price	$0.80	$8.71
P/E Ratio	N/A	N/A
P/S Ratio	0.98x	7,526.09x
EV/Sales	1.15x	4,822.94x
EV/EBITDA	49.22x	0.00x
P/B Ratio	9.58x	0.97x
P/FCF Ratio	7.30x	N/A
EV/FCF	8.54x	-0.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.35x	16,911.71x
Revenue & Growth
Revenue (TTM)	$219M	$27K
Revenue Growth (YoY)	7.5%	-55.0%
Forward Rev Growth	-33.0%	7184.7%
Profitability
Gross Margin (TTM)	81.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1.9%	-669059.3%
Net Margin (TTM)	-13.5%	-920285.2%
FCF Margin (TTM)	13.4%	-648763.0%
Net Income (TTM)	$-30M	$-248M
FCF (TTM)	$29M	$-175M
EPS (TTM)	-$0.11	-$10.64
ROE (TTM)	-9374.0%	-9162.0%
ROA (TTM)	-817.0%	-7050.0%
ROIC (TTM)	-1321.0%	-9162.0%
Financial Health
Cash	$156M	$73M
Debt	$192M	$0
Net Cash/Debt	$-37M	$73M
Current Ratio (TTM)	1.43x	5.36x
Quick Ratio (TTM)	1.31x	5.12x
Debt/Equity (TTM)	7.69x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.20	-0.04
52W Performance	-71.9%	-52.3%
YTD Performance	-48.3%	-69.9%
% from 52W High	-75.0%	-80.6%
% from 52W Low	0.0%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.60x	0.00x
FCF Yield (TTM)	13.7%	-86.2%
Earnings Yield (TTM)	-13.8%	-122.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	21.0	-648,818.0
EV/GP/RG	N/A	N/A
Ticker research	View AKBA research	View LYEL research

Valuation

P/S Ratio

AKBA

0.98x

LYEL

7,526.09x

EV/FCF

LYEL

-0.74x

AKBA

8.54x

Growth & revenue

Revenue Growth TTM

AKBA

7.5%

LYEL

-55.0%

Forward Revenue Growth

LYEL

7184.7%

AKBA

-33.0%

Profitability & performance

Gross Margin

AKBA

81.5%

LYEL

0.0%

ROE

LYEL

-9162.0%

AKBA

-9374.0%

FCF Yield %

AKBA

13.7%

LYEL

-86.2%

52-Week Performance

LYEL

-52.3%

AKBA

-71.9%

Detailed metrics comparison

AKBA

Akebia Therapeutics Inc

LYEL

Lyell Immunopharma Inc

Market Cap

AKBA$215M

LYEL$203M

Enterprise Value

AKBA$252M

LYEL$130M

Price

AKBA$0.80

LYEL$8.71

P/E Ratio

AKBAN/A

LYELN/A

P/S Ratio

AKBA0.98x

LYEL7,526.09x

EV/Sales

AKBA1.15x

LYEL4,822.94x

EV/EBITDA

AKBA49.22x

LYEL0.00x

P/B Ratio

AKBA9.58x

LYEL0.97x

P/FCF Ratio

AKBA7.30x

LYELN/A

EV/FCF

AKBA8.54x

LYEL-0.74x

PEG Ratio

AKBAN/A

LYELN/A

Forward P/E (NTM)

AKBAN/A

LYELN/A

Forward P/S (NTM)

AKBA1.35x

LYEL16,911.71x

Revenue (TTM)

AKBA$219M

LYEL$27K

Revenue Growth (YoY)

AKBA7.5%

LYEL-55.0%

Forward Rev Growth

AKBA-33.0%

LYEL7184.7%

Gross Margin (TTM)

AKBA81.5%

LYEL0.0%

Operating Margin (TTM)

AKBA0.0%

LYEL0.0%

EBITDA Margin (TTM)

AKBA-1.9%

LYEL-669059.3%

Net Margin (TTM)

AKBA-13.5%

LYEL-920285.2%

FCF Margin (TTM)

AKBA13.4%

LYEL-648763.0%

Net Income (TTM)

AKBA$-30M

LYEL$-248M

FCF (TTM)

AKBA$29M

LYEL$-175M

EPS (TTM)

AKBA-$0.11

LYEL-$10.64

ROE (TTM)

AKBA-9374.0%

LYEL-9162.0%

ROA (TTM)

AKBA-817.0%

LYEL-7050.0%

ROIC (TTM)

AKBA-1321.0%

LYEL-9162.0%

Cash

AKBA$156M

LYEL$73M

Debt

AKBA$192M

LYEL$0

Net Cash/Debt

AKBA$-37M

LYEL$73M

Current Ratio (TTM)

AKBA1.43x

LYEL5.36x

Quick Ratio (TTM)

AKBA1.31x

LYEL5.12x

Debt/Equity (TTM)

AKBA7.69x

LYEL0.00x

Debt/Assets (TTM)

AKBA0.0%

LYEL0.0%

Interest Coverage (TTM)

AKBAN/A

LYELN/A

Net Debt/EBITDA (TTM)

AKBA0.00x

LYEL0.00x

Beta

AKBA0.20

LYEL-0.04

52W Performance

AKBA-71.9%

LYEL-52.3%

YTD Performance

AKBA-48.3%

LYEL-69.9%

% from 52W High

AKBA-75.0%

LYEL-80.6%

% from 52W Low

AKBA0.0%

LYEL6.1%

Asset Turnover (TTM)

AKBA0.60x

LYEL0.00x

FCF Yield (TTM)

AKBA13.7%

LYEL-86.2%

Earnings Yield (TTM)

AKBA-13.8%

LYEL-122.3%

Dividend Yield (TTM)

AKBAN/A

LYELN/A

Rule of 40

AKBA21.0

LYEL-648,818.0

EV/GP/RG

AKBAN/A

LYELN/A

Ticker research

View AKBA research View LYEL research

Metric	AKBA Akebia Therapeutics Inc	LYEL Lyell Immunopharma Inc
Market & Valuation
Market Cap	$215M	$203M
Enterprise Value	$252M	$130M
Price	$0.80	$8.71
P/E Ratio	N/A	N/A
P/S Ratio	0.98x	7,526.09x
EV/Sales	1.15x	4,822.94x
EV/EBITDA	49.22x	0.00x
P/B Ratio	9.58x	0.97x
P/FCF Ratio	7.30x	N/A
EV/FCF	8.54x	-0.74x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.35x	16,911.71x
Revenue & Growth
Revenue (TTM)	$219M	$27K
Revenue Growth (YoY)	7.5%	-55.0%
Forward Rev Growth	-33.0%	7184.7%
Profitability
Gross Margin (TTM)	81.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1.9%	-669059.3%
Net Margin (TTM)	-13.5%	-920285.2%
FCF Margin (TTM)	13.4%	-648763.0%
Net Income (TTM)	$-30M	$-248M
FCF (TTM)	$29M	$-175M
EPS (TTM)	-$0.11	-$10.64
ROE (TTM)	-9374.0%	-9162.0%
ROA (TTM)	-817.0%	-7050.0%
ROIC (TTM)	-1321.0%	-9162.0%
Financial Health
Cash	$156M	$73M
Debt	$192M	$0
Net Cash/Debt	$-37M	$73M
Current Ratio (TTM)	1.43x	5.36x
Quick Ratio (TTM)	1.31x	5.12x
Debt/Equity (TTM)	7.69x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.20	-0.04
52W Performance	-71.9%	-52.3%
YTD Performance	-48.3%	-69.9%
% from 52W High	-75.0%	-80.6%
% from 52W Low	0.0%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.60x	0.00x
FCF Yield (TTM)	13.7%	-86.2%
Earnings Yield (TTM)	-13.8%	-122.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	21.0	-648,818.0
EV/GP/RG	N/A	N/A
Ticker research	View AKBA research	View LYEL research